ASX Announcements

ASX Announcements

Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising.

Date Title  
20 September 2022 Change of Director's Interest Notice
12 September 2022 Change of Director's Interest Notice
31 August 2022 MSB Annual Financial Results and Operational Highlights
31 August 2022 Annual Financial Results Presentation
31 August 2022 Preliminary Final Report
30 August 2022 Mesoblast 2022 Full Year Financial Results Webcast
18 August 2022 Director Appointment
18 August 2022 Initial Director's Interest Notice
18 August 2022 Final Director's Interest Notice
16 August 2022 Ceasing to be a substantial holder - Tiga Trading Pty Ltd
16 August 2022 Ceasing to be a substantial holder from TEK
16 August 2022 Ceasing to be a substantial holder from TOP
16 August 2022 Change in substantial holding
12 August 2022 Cleansing Notice
12 August 2022 Appendix 2A
09 August 2022 Appendix 3B
09 August 2022 US$45 Million Private Placement to Major Shareholders
09 August 2022 Reinstatement to Quotation
08 August 2022 Voluntary Suspension
04 August 2022 Trading Halt
04 August 2022 Pause in Trading
29 July 2022 Quarterly Activities/Appendix 4C Cash Flow Report
19 July 2022 Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
14 July 2022 Appendix 3H and Appendix 3Y
12 July 2022 Rexlemestrocel-L to be Highlighted on Heart Failure Panel
21 June 2022 Mesoblast CLBP Event with Key Opinion Leaders
21 June 2022 Chronic Low Back Pain KOL Event Presentation
14 June 2022 Litigation Update
09 June 2022 Mesoblast to Host KOL Event on Chronic Low Back Pain
01 June 2022 Third Quarter Results Presentation
01 June 2022 MSB Q3 Financial Results and Operational Highlights
01 June 2022 Third Quarter Financial Results on Form 6-K
31 May 2022 Mesoblast Q3 Financial Results Webcast
31 May 2022 Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
30 May 2022 Ceasing to be a substantial holder
20 May 2022 Becoming a substantial holder
19 May 2022 Litigation Update
03 May 2022 Ceasing to be a substantial holder
02 May 2022 Ceasing to be a substantial holder
29 April 2022 Quarterly Activities/Appendix 4C Cash Flow Report
19 April 2022 Becoming a substantial holder
14 April 2022 Appendix 3G and Appendix 3H
06 April 2022 Company Secretary Appointment
29 March 2022 Becoming a substantial holder
28 March 2022 Initial Director's Interest Notice
24 March 2022 Director Appointment
04 March 2022 S&P DJI Announces March 2022 Quarterly Rebalance
25 February 2022 Final Director's Interest Notice
25 February 2022 MSB Q2 Financial Results and Operational Highlights
25 February 2022 Second Quarter Results Presentation
25 February 2022 Half Yearly Report and Accounts
24 February 2022 Mesoblast Q2 Financial Results Webcast
21 February 2022 Ulcerative Colitis & Crohns Results Presented at ECCO
02 February 2022 Mesoblast Appoints Dr Eric Rose as Chief Medical Officer
31 January 2022 Appendix 4C Quarterly Activity Report
25 January 2022 MSB Presents at Edison Group Global Healthcare Conference
18 January 2022 Cleansing Notice and Appendix 2A
18 January 2022 Proposed issue of securities - MSB
17 January 2022 Appendix 3G, Appendix 3H and Appendix 3Y
12 January 2022 36-Month Results of Phase 3 Trial in Chronic Low Back Pain
12 January 2022 Biotech Showcase 2022 Presentation
06 January 2022 Prospectus for Warrants Related to Oaktree Debt Refinance

Share Price :    as of Sep 10, 2022